Amgen’s Olpasiran Slashes Lp(a) Levels | AHA Study Rollout - Cardiac Wire

Skip to content

Your work email

Thank you! Please check your email for confirmation.

Something went wrong, please try again.

Top Stories
Newsletters
Shows
Sponsor

Your work email

Thank you! Please check your email for confirmation.

Something went wrong, please try again.

Thank you!

Something went wrong.

Get twice-weekly insights on the biggest stories shaping cardiology.

Thank you! Please check your email for confirmation.

Something went wrong, please try again.

You might also like

Cardiac Wire #416 November 12, 2026

The First Ever Factor XIa Gets Approved for Secondary Stroke

Cardiac Wire #415 November 9, 2026

TAVR’s PROGRESS, Interventional Imaging, and BSCI’s Blackstone Funds

Cardiac Wire #414 November 4, 2026

The Top Trends and Research From TCT 2026

The Imaging Wire
Digital Health Wire
The Bio Wire
Sponsor

© 2021 Cardiac Wire

Privacy Policy
Terms of Service

This content is exclusive to subscribers

Log in or join by entering your email below.

Your work email

Thank you! Please check your email for confirmation.

Something went wrong, please try again.

Completely free. Every Monday and Thursday.

CW Phone Square